Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vaccination strategies for lymphomas.

Mohammed M Dar1, Larry W Kwak

  • 1National Cancer Institute-Frederick, Building 567, Room 203, Frederick, MD 21702-1201, USA.

Current Oncology Reports
|August 5, 2003
PubMed
Summary

Idiotype vaccines, targeting unique lymphoma antigens, show promise in clinical trials. Future research aims to prove efficacy and develop convenient, alternative vaccination methods for improved cancer immunotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Harnessing Neoantigen-specific T Cells for Precision Immunotherapy in Hematologic Malignancies.

Blood·2026
Same author

Vaccine-derived T-cell responses are insufficient to generate protective immunity to SARS-CoV-2.

Scientific reports·2026
Same author

Polatuzumab Vedotin Combined With R-ICE (PolaR-ICE) as Second-Line Therapy in Diffuse Large B-Cell Lymphoma.

American journal of hematology·2026
Same author

Predictive markers for the efficacy of CAR T-cell therapy: the interplay between CAR T-cell fitness and systemic immunity.

Blood advances·2025
Same author

Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetration.

Blood advances·2025
Same author

Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma.

Molecular therapy. Methods & clinical development·2025

Area of Science:

  • Oncology
  • Immunology
  • Vaccine Development

Background:

  • Lymphoma treatment has advanced with tumor-specific targets like idiotypes.
  • Idiotype vaccines utilize unique variable regions of the clonal antigen receptor.
  • Animal models have significantly aided the development of human idiotype vaccine trials.

Purpose of the Study:

  • To review the development and progress of idiotype vaccination strategies for lymphomas.
  • To highlight the current understanding of immune response mechanisms in immunotherapy.
  • To outline ongoing research in improving idiotype vaccine production and efficacy.

Main Methods:

  • Review of human clinical trials and animal models for idiotype vaccines.
  • Analysis of basic mechanisms underlying immune response induction.
  • Exploration of novel immunotherapeutic strategies and vaccination approaches.

Main Results:

  • Strong evidence suggests clinical benefit from idiotype vaccines, though not formally proven.
  • Significant advancements in understanding immune responses have spurred new immunotherapeutic designs.
  • Progress in developing more convenient idiotype vaccine production methods.

Conclusions:

  • Idiotype vaccines represent a key development in lymphoma immunotherapy.
  • Further research is needed to definitively prove clinical efficacy.
  • Alternative strategies like genetic vaccination and cell-based therapies are under investigation.

Related Experiment Videos